Celltrion is a leading biopharmaceutical company based in South Korea, specialising in the research, development, and manufacture of biosimilars and innovative drugs. Established as a pioneering force in the Korean pharmaceutical industry, Celltrion achieved a remarkable milestone by launching the world’s first antibody biosimilar from a country with a relatively underdeveloped pharmaceutical sector. The company has successfully ventured into numerous uncharted areas and aims to continue its growth as a global biopharmaceutical entity, with unique approaches to small molecule pharmaceuticals and emerging businesses such as the Ubiquitous-healthcare platform.

Services include:
– APIs (Active Pharmaceutical Ingredients)
– Biologics
– Biosimilars
– Contract Manufacturing (CMO/CDMO)

Celltrion remains committed to providing more affordable biosimilar monoclonal antibodies to patients who previously had limited access to advanced treatments.